Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia
- PMID: 20728875
- PMCID: PMC3005969
- DOI: 10.1016/j.biopsych.2010.07.004
Effects of an alpha 7-nicotinic agonist on default network activity in schizophrenia
Abstract
Background: 3-(2,4-dimethoxybenzylidene)-anabaseine (DMXB-A) is a partial agonist at α7 nicotinic acetylcholine receptors that has been evaluated clinically for treatment of schizophrenia. This study examined the effects of DMXB-A on default network activity as a biomarker for drug effects on pathologic brain function associated with schizophrenia.
Methods: Placebo and two doses of DMXB-A were administered in a random, double-blind crossover design during a Phase 2 study of DMXB-A. Functional magnetic resonance imaging was performed on 16 nonsmoking patients with schizophrenia while they performed a simple eye movement task. Independent component analysis was used to identify the default network component. Default network changes were evaluated in the context of a polymorphism in CHRNA7, the α7-nicotinic acetylcholine receptor subunit gene, which was previously found to be associated with schizophrenia.
Results: Compared with placebo, both 150 and 75 mg twice daily DMXB-A altered default network activity, including a reduction in posterior cingulate, inferior parietal cortex, and medial frontal gyrus activity and an increase in precuneus activity. The most robust difference, posterior cingulate activity reduction, was affected by CHRNA7 genotype.
Conclusions: The observed DMXB-A-related changes are consistent with improved default network function in schizophrenia. Pharmacogenetic analysis indicates mediation of the effect through the α7-nicotinic receptor. These results further implicate nicotinic cholinergic dysfunction in the disease and suggest that default network activity may be a useful indicator of biological effects of novel therapeutic agents.
Trial registration: ClinicalTrials.gov NCT00100165.
Copyright © 2011 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
Figures
Comment in
-
α7 Nicotinic receptor agonists as cognitive treatments: is less (or less often) more?Biol Psychiatry. 2011 Jan 1;69(1):5-6. doi: 10.1016/j.biopsych.2010.11.004. Biol Psychiatry. 2011. PMID: 21145443 No abstract available.
Similar articles
-
Functional magnetic resonance imaging of effects of a nicotinic agonist in schizophrenia.Neuropsychopharmacology. 2010 Mar;35(4):938-42. doi: 10.1038/npp.2009.196. Epub 2009 Dec 2. Neuropsychopharmacology. 2010. PMID: 19956085 Free PMC article. Clinical Trial.
-
Initial phase 2 trial of a nicotinic agonist in schizophrenia.Am J Psychiatry. 2008 Aug;165(8):1040-7. doi: 10.1176/appi.ajp.2008.07071135. Epub 2008 Apr 1. Am J Psychiatry. 2008. PMID: 18381905 Free PMC article. Clinical Trial.
-
Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia.Arch Gen Psychiatry. 2006 Jun;63(6):630-8. doi: 10.1001/archpsyc.63.6.630. Arch Gen Psychiatry. 2006. PMID: 16754836 Clinical Trial.
-
α7-nicotinic acetylcholine receptor agonists for cognitive enhancement in schizophrenia.Annu Rev Med. 2014;65:245-61. doi: 10.1146/annurev-med-092112-142937. Epub 2013 Oct 9. Annu Rev Med. 2014. PMID: 24111888 Review.
-
Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor.Handb Exp Pharmacol. 2012;(213):211-32. doi: 10.1007/978-3-642-25758-2_8. Handb Exp Pharmacol. 2012. PMID: 23027417 Free PMC article. Review.
Cited by
-
Alpha7 Nicotinic Receptors as Therapeutic Targets in Schizophrenia.Nicotine Tob Res. 2019 Feb 18;21(3):349-356. doi: 10.1093/ntr/nty034. Nicotine Tob Res. 2019. PMID: 30137618 Free PMC article. Review.
-
Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.Neuropsychopharmacology. 2012 Jan;37(1):16-42. doi: 10.1038/npp.2011.199. Epub 2011 Sep 28. Neuropsychopharmacology. 2012. PMID: 21956443 Free PMC article. Review.
-
Kynurenine pathway and cognitive impairments in schizophrenia: Pharmacogenetics of galantamine and memantine.Schizophr Res Cogn. 2016 Jun;4:4-9. doi: 10.1016/j.scog.2016.02.001. Schizophr Res Cogn. 2016. PMID: 27069875 Free PMC article.
-
Therapeutic Applications of Nicotinic Stimulation: Successes, Failures, and Future Prospects.Nicotine Tob Res. 2019 Feb 18;21(3):345-348. doi: 10.1093/ntr/nty189. Nicotine Tob Res. 2019. PMID: 30203054 Free PMC article. No abstract available.
-
Promoter methylation and tissue-specific transcription of the α7 nicotinic receptor gene, CHRNA7.J Mol Neurosci. 2012 Jun;47(2):389-400. doi: 10.1007/s12031-011-9663-7. Epub 2011 Nov 4. J Mol Neurosci. 2012. PMID: 22052086
References
-
- Freedman R, Hall M, Adler LE, Leonard S. Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. BiolPsychiatry. 1995;38:22–33. - PubMed
-
- Leonard S, Gault J, Hopkins J, Logel J, Vianzon R, Short M, et al. Association of promoter variants in the alpha7 nicotinic acetylcholine receptor subunit gene with an inhibitory deficit found in schizophrenia. ArchGenPsychiatry. 2002;59:1085–1096. - PubMed
-
- Hughes JR, Hatsukami DK, Mitchell JE, Dahlgren LA. Prevalence of smoking among psychiatric outpatients. AmJPsychiatry. 1986;143:993–997. - PubMed
-
- de Leon J, Dadvand M, Canuso C, White AO, Stanilla JK, Simpson GM. Schizophrenia and smoking: an epidemiological survey in a state hospital. AmJPsychiatry. 1995;152:453–455. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical